Our Approved

Medicines

Our Product

^{The Product Information provided below is intended for residents of the U.S. only.}

Neurocrine Biosciences/AbbVie Collaboration

After discovering and developing elagolix through Phase 2 studies in endometriosis, we out-licensed the global rights to elagolix to AbbVie in 2010. AbbVie is responsible for all development and commercialization costs of elagolix. AbbVie launched ORILISSA® (elagolix tablets) in the United States and Canada in August and November 2018, respectively.

In June 2020, AbbVie launched ORIAHNN® (elagolix, estradiol and norethindrone acetate capsules and elagolix capsules) in the United States. We receive royalties at tiered percentage rates on AbbVie net sales of products containing elagolix.